Arcoma (ARCOMA) Q4 2025 earnings summary

Executive summary

• Achieved profitability in every quarter of 2025 despite lower volumes and currency headwinds, supported by strong cash flow and a robust balance sheet.

• Maintained cost base despite inflation, demonstrating business model resilience and scalability for future volume increases.

• Focused on innovation, product development, and expanding sales channels, particularly in Europe, which saw 33% growth in Q4.

• North America experienced a 36% decline in growth, while Asia saw an 87% decrease in Q4 compared to the previous year.

Financial highlights

• Q4 2025 net sales: 34,659 KSEK (down from 36,802 KSEK in Q4 2024).

• Q4 EBITDA: 3,355 KSEK (down from 4,420 KSEK); EBITDA margin 10% (13%).

• Q4 pre-tax profit: 1,727 KSEK (down from 3,307 KSEK); EPS: 0.10 SEK (0.35 SEK).

• Full-year 2025 net sales: 130,800 KSEK (down from 156,807 KSEK in 2024).

• Full-year EBITDA: 13,577 KSEK (down from 21,590 KSEK); pre-tax profit: 6,306 KSEK (13,768 KSEK); EPS: 0.35 SEK (0.85 SEK).

• Q4 cash flow from operations: 12,930 KSEK (4,802 KSEK in Q4 2024); full-year operating cash flow: 18,720 KSEK (18,844 KSEK in 2024).

• Cash and cash equivalents at year-end: 35,317 KSEK (13,376 KSEK at end of 2024).

Outlook and guidance

• Positioned for scalable growth as demand recovers, with continued investment in R&D and product innovation.

• Ongoing focus on cost control, efficiency, and expanding product offerings through acquisitions.

• Positive underlying demand in North America, but short-term uncertainty and timing issues persist.